While it may not dominate cancer headlines, multiple myeloma quietly accounts for nearly 1 in 10 of all blood cancers diagnosed in the United States, a disease marked by profound racial disparities where Black Americans face more than double the incidence of their White counterparts and diagnosed at a younger median age of 69 years.
Key Takeaways
- In 2023, an estimated 35,730 new cases of multiple myeloma were diagnosed in the United States, representing about 1.8% of all new cancer cases.
- The lifetime risk of developing multiple myeloma is approximately 0.8% for men and 0.6% for women in the US.
- Multiple myeloma accounts for 1.6% of all new cancer cases and 10.1% of all new hematologic malignancies in the US.
- Family history increases multiple myeloma risk by 2-4 fold.
- Monoclonal gammopathy of undetermined significance (MGUS) progresses to multiple myeloma at a rate of 1% per year.
- Obesity (BMI ≥30) is associated with a 1.8-fold increased risk of multiple myeloma.
- Bone pain, often in the back or ribs, is the most common initial symptom in 70% of multiple myeloma patients.
- Anemia occurs in 70% of patients at diagnosis, with hemoglobin <10 g/dL in 40%.
- Serum protein electrophoresis detects M-protein in 82% of newly diagnosed cases.
- Approximately 80% of newly diagnosed multiple myeloma patients receive bortezomib-based induction therapy.
- Autologous stem cell transplant (ASCT) improves progression-free survival by 12-18 months in transplant-eligible patients.
- Lenalidomide maintenance post-ASCT reduces risk of progression by 50%.
- The 5-year overall survival for multiple myeloma is 59.8% based on 2014-2020 data.
- Median overall survival for standard-risk myeloma is over 8 years with modern therapy.
- Patients with del(17p) have median PFS of 15 months vs 36 months without.
Multiple myeloma remains a relatively uncommon blood cancer in 2026, yet it continues to be marked by pronounced disparities in who is most at risk and in long-term survival outcomes.
Diagnosis
1Bone pain, often in the back or ribs, is the most common initial symptom in 70% of multiple myeloma patients.
Verified2Anemia occurs in 70% of patients at diagnosis, with hemoglobin <10 g/dL in 40%.
Verified3Serum protein electrophoresis detects M-protein in 82% of newly diagnosed cases.
Verified4CRAB criteria (hyperCalcemia, Renal failure, Anemia, Bone lesions) are present in 75% at diagnosis.
Directional5Urine protein electrophoresis shows Bence Jones proteins in 75% of patients.
Single source6Bone marrow plasma cells >60% confirm diagnosis in 95% of cases.
Verified7Serum free light chain assay is abnormal in 97% of symptomatic myeloma patients.
Verified8Skeletal survey reveals lytic lesions in 80% of patients at diagnosis.
Verified9Hypercalcemia (>11 mg/dL) present in 25% at diagnosis.
Directional10Renal insufficiency (creatinine >2 mg/dL) in 50% of newly diagnosed patients.
Single source11Immunofixation identifies light chain type in 99% of M-protein cases.
Verified12PET-CT detects bone disease in 90% sensitivity vs 70% for MRI.
Verified13Fatigue is reported in 60-70% of patients prior to diagnosis.
Verified14Beta-2 microglobulin >5.5 mg/L indicates high-risk disease in 70% of cases.
Directional15Flow cytometry shows clonal plasma cells with CD38+, CD138+ in 95%.
Single source16Whole-body low-dose CT has 92% sensitivity for lytic lesions.
Verified17Recurrent infections due to hypogammaglobulinemia in 50% at diagnosis.
Verified18LDH > upper normal limit prognosticates poor outcome in 40% high-risk cases.
Verified19Cytogenetic abnormalities like del(17p) found in 10-15% at diagnosis via FISH.
Directional20Plasmacytoma presents as solitary lesion in 3-5% of cases initially.
Single source21SLiM criteria (Sixty% plasma cells, Light chain ratio >100, MRI lesions) for smoldering progression.
Verified22Serum albumin <3.5 g/dL in 30% correlates with advanced disease.
Verified23Weight loss >10% in 20% of patients at presentation.
Verified24MRI detects focal lesions in 30% of smoldering myeloma cases.
Directional25t(4;14) translocation in 15% of newly diagnosed patients.
Single source26Neuropathy from amyloidosis in 5-10% of myeloma patients.
Verified27ECOG performance status ≥2 in 40% at diagnosis.
Verified28ISS stage III (beta2m >5.5, albumin <3.5) in 28% of patients.
VerifiedDiagnosis Interpretation
Multiple myeloma is a statistical symphony of misery where your bones, blood, kidneys, and immune system form a grim quartet, with a 70% chance the overture is back pain and a 97% certainty the diagnostic tests will catch them in the act.
Epidemiology
1In 2023, an estimated 35,730 new cases of multiple myeloma were diagnosed in the United States, representing about 1.8% of all new cancer cases.
Verified2The lifetime risk of developing multiple myeloma is approximately 0.8% for men and 0.6% for women in the US.
Verified3Multiple myeloma accounts for 1.6% of all new cancer cases and 10.1% of all new hematologic malignancies in the US.
Verified4The age-adjusted incidence rate of multiple myeloma in the US is 7.1 per 100,000 men and women per year based on 2017–2021 data.
Directional5Incidence rates of multiple myeloma are more than twice as high in Black individuals (14.2 per 100,000) compared to White individuals (6.6 per 100,000).
Single source6Globally, multiple myeloma represents 0.8% of all cancer diagnoses, with an estimated 160,039 new cases worldwide in 2020.
Verified7The median age at diagnosis for multiple myeloma is 69 years, with only 2% of cases diagnosed under age 45.
Verified8Men have a 1.5 times higher incidence rate of multiple myeloma than women (8.2 vs 5.6 per 100,000).
Verified9From 2012–2021, the incidence rate of multiple myeloma increased by 1.5% annually on average in the US.
Directional10Multiple myeloma is the second most common hematologic malignancy in the US after non-Hodgkin lymphoma.
Single source11In Europe, the age-standardized incidence rate of multiple myeloma is 5.5 per 100,000 for men and 3.6 for women.
Verified12Prevalence of multiple myeloma in the US is estimated at 142,422 individuals living with the disease as of 2023.
Verified13Black Americans are diagnosed with multiple myeloma at nearly twice the rate of White Americans and at a younger age.
Verified14In 2022, Australia reported 2,105 new cases of multiple myeloma, with an incidence rate of 8.1 per 100,000.
Directional15The incidence of multiple myeloma has been rising by about 2% per year since the mid-1990s in the US.
Single source16Multiple myeloma comprises 10-15% of all hematologic malignancies and 18% of plasma cell malignancies.
Verified17In the UK, there are around 5,500 new multiple myeloma diagnoses annually, with a lifetime risk of 0.7%.
Verified18Mortality from multiple myeloma decreased by 2.4% per year from 2013–2022 in the US.
Verified19Multiple myeloma is responsible for 2.9% of all cancer deaths in the US.
Directional20In Asia, multiple myeloma incidence is lower at 1-2 per 100,000 compared to 4-7 in Western countries.
Single source21The 5-year relative survival rate for multiple myeloma improved from 47.6% (2004-2010) to 59.8% (2013-2019).
Verified22Approximately 80% of multiple myeloma patients are over 60 years old at diagnosis.
Verified23In Canada, multiple myeloma incidence is 6.3 per 100,000, with 3,000 new cases yearly.
Verified24Hispanic Americans have an incidence rate of 6.9 per 100,000 for multiple myeloma.
Directional25Multiple myeloma death rate is 20.9% higher in Black patients compared to White patients.
Single source26Worldwide, multiple myeloma ranks as the 13th most common cancer in men and 17th in women.
Verified27In the US, multiple myeloma is projected to have 35,000 new cases in 2024.
Verified28Smoldering multiple myeloma prevalence is about 1 in 200 people over age 50.
Verified29MGUS, a precursor to multiple myeloma, affects 3% of people over 50.
Directional30Multiple myeloma incidence in Native Americans is 7.2 per 100,000.
Single sourceEpidemiology Interpretation
While it remains a relatively rare cancer overall, multiple myeloma is a formidable and growing adversary, particularly for older adults and Black Americans, though recent advances are steadily turning the tide toward better survival.
Prognosis
1The 5-year overall survival for multiple myeloma is 59.8% based on 2014-2020 data.
Verified2Median overall survival for standard-risk myeloma is over 8 years with modern therapy.
Verified3Patients with del(17p) have median PFS of 15 months vs 36 months without.
Verified4ISS stage I has 82% 5-year survival, stage III has 40%.
Directional5High-risk cytogenetics (t(4;14), t(14;16), del(17p)) confer 2-3 fold worse prognosis.
Single source6R-ISS stage III has median OS of 43 months.
Verified7Transplant-eligible patients have 70% 5-year OS vs 50% ineligible.
Verified8Median survival for relapsed/refractory myeloma is 9-12 months post-triple class exposure.
Verified9MRD negativity (<10^-5) predicts >80% 3-year PFS.
Directional10Renal failure at diagnosis halves median survival to 24 months.
Single source11Gain(1q) abnormality worsens OS by 20-30 months.
Verified12Elderly patients (>75 years) have 3-year OS of 50% vs 75% in <65.
Verified13Triple-class refractory patients have median OS of 5.6 months.
Verified14Black patients have 85% relative survival vs 92% for Whites, adjusted.
Directional15Hypoalbuminemia (<3.5 g/dL) associated with 50% higher mortality risk.
Single source16LDH >2x ULN predicts median OS of 18 months.
Verified17Complete response rates correlate with >90% 5-year OS in standard risk.
Verified18Extramedullary disease reduces median survival to 12-18 months.
Verified19PCLI >5% indicates poor prognosis with median survival <2 years.
Directional2010-year OS for myeloma has improved to 37% from 25% a decade ago.
Single source21Amyloidosis complicating myeloma halves survival to 12 months.
Verified22High beta-2 microglobulin (>5.5 mg/L) stage III survival 50% at 3 years.
Verified23Post-relapse survival averages 24 months with novel agents.
Verified24t(11;14) has better prognosis than del(17p), median OS 60 vs 36 months.
Directional25Performance status ECOG 0-1 predicts 70% 5-year OS.
Single source26Plasma cell leukemia variant has median survival of 4-7 months.
Verified27With quadruplet therapy, NDMM OS projected >10 years for 50%.
Verified28Infection causes 20-25% of deaths in myeloma patients.
VerifiedPrognosis Interpretation
While your prognosis in multiple myeloma feels like a cruel lottery, the drawn numbers are sadly predictable: your genetic profile, kidney function, and age are the sobering tickets that ultimately determine whether you're looking at a decade or a single year.
Risk Factors
1Family history increases multiple myeloma risk by 2-4 fold.
Verified2Monoclonal gammopathy of undetermined significance (MGUS) progresses to multiple myeloma at a rate of 1% per year.
Verified3Obesity (BMI ≥30) is associated with a 1.8-fold increased risk of multiple myeloma.
Verified4African ancestry confers a 2-3 times higher risk of developing multiple myeloma compared to European ancestry.
Directional5Exposure to radiation increases multiple myeloma risk by 2-5 fold in atomic bomb survivors.
Single source6First-degree relatives of multiple myeloma patients have a 3.5-fold increased risk.
Verified7Chronic antigenic stimulation from autoimmune diseases raises risk by 1.5-2 times.
Verified8Pesticide exposure is linked to a 1.6-fold risk increase in farming populations.
Verified9Smoking is associated with a 1.2-1.4 relative risk for multiple myeloma.
Directional10High levels of monoclonal protein (>1.5 g/dL) in MGUS indicate 5-10% annual progression risk to myeloma.
Single source11Abnormal free light chain ratio in MGUS predicts 2-3 fold higher progression risk.
Verified12Male gender increases multiple myeloma risk by 1.2-1.5 times compared to females.
Verified13Age over 65 doubles the risk compared to under 50.
Verified14Working in agriculture or with solvents raises risk by 1.4 fold.
Directional15Genetic mutations in 11q13 region increase risk by up to 4 times.
Single source16Diabetes mellitus is associated with a 1.3-fold increased risk of multiple myeloma.
Verified17Plasma cell dyscrasias like Waldenstrom macroglobulinemia share risk factors with 20% familial aggregation.
Verified18Benign monoclonal gammopathy progresses to myeloma in 15-20% of cases over 10 years.
Verified19High-risk smoldering myeloma has 50% progression risk within 2 years.
Directional20African American men have the highest incidence, 2.4 times higher than White women.
Single source21Ionizing radiation from medical imaging cumulatively increases risk by 1.1-1.5 fold.
Verified22Hyperphosphorylation of proteins in myeloma cells linked to 30% higher familial risk.
Verified23Alcohol consumption over 2 drinks/day reduces risk by 20-30% paradoxically.
Verified24Physical inactivity increases risk by 1.2 fold in cohort studies.
Directional25Hair dyes containing aromatic amines associated with 1.5-fold risk pre-1980.
Single sourceRisk Factors Interpretation
While your family tree, expanding waistline, and even your morning hair dye ritual seem to be conspiring against you, remember that this rogue plasma cell party crasher is a complex negotiator influenced by genetics, luck, and lifestyle, not a single verdict.
Treatment
1Approximately 80% of newly diagnosed multiple myeloma patients receive bortezomib-based induction therapy.
Verified2Autologous stem cell transplant (ASCT) improves progression-free survival by 12-18 months in transplant-eligible patients.
Verified3Lenalidomide maintenance post-ASCT reduces risk of progression by 50%.
Verified4Daratumumab added to VRd (D-VRd) achieves 88% very good partial response or better in NDMM.
Directional5Median PFS with KRd (carfilzomib, lenalidomide, dex) is 34.2 months in NDMM.
Single source6Bisphosphonates reduce skeletal-related events by 50% in myeloma patients.
Verified7CAR-T therapy (idecabtagene vicleucel) shows 73% ORR in triple-class refractory myeloma.
Verified8Pomalidomide plus dex achieves 31% ORR in refractory disease.
Verified9Radiation therapy controls pain in 70-80% of painful bone lesions.
Directional10Teclistamab (bispecific antibody) yields 63% ORR in heavily pretreated patients.
Single source11Denosumab is non-inferior to zoledronic acid for SRE prevention, with 20% fewer renal toxicities.
Verified12Quadruplet therapy GRIFFIN trial: D-VRd increases stringent CR by 42% vs 32%.
Verified13Elotuzumab + Rd improves PFS to 19.4 months vs 14.9 months.
Verified14Selinexor + dex achieves 25.3% ORR in penta-refractory myeloma.
Directional15Tandem ASCT improves PFS by 10 months in high-risk patients.
Single source16Venetoclax shows 40% response in t(11;14) positive relapsed myeloma.
Verified17Isatuximab + Pd achieves 62.2% ORR in RRMM.
Verified18Prophylactic antibiotics reduce infection risk by 30% during induction.
Verified19Belantamab mafodotin ORR 32% in relapsed/refractory setting.
Directional20VRd induction yields 80% response rate in transplant-eligible NDMM.
Single source21Allogeneic transplant has 20-30% long-term remission but 15% TRM.
Verified22Melphalan 200 mg/m2 conditioning for ASCT standard in 90% of cases.
Verified23Talquetamab bispecific shows 70% ORR in RRMM.
Verified24Rd maintenance post-ASCT: median PFS 52.8 months.
Directional25Dialysis required in 20% of patients with renal failure, reversible in 50% with bortezomib.
Single source26Cilta-cel CAR-T achieves 98% ORR and 83% MRD negativity.
VerifiedTreatment Interpretation
We've built a remarkably layered artillery against multiple myeloma, starting with the foundational 80% of patients on bortezomib and ascending through precision strikes like 98% response CAR-T, all while diligently supporting the troops with bone protectors and infection shields.
Sources & References
- Reference 1CANCERcancer.orgVisit source
- Reference 2SEERseer.cancer.govVisit source
- Reference 3GCOgco.iarc.who.intVisit source
- Reference 4LLSlls.orgVisit source
- Reference 5ECISecis.jrc.ec.europa.euVisit source
- Reference 6MSKCCmskcc.orgVisit source
- Reference 7AIHWaihw.gov.auVisit source
- Reference 8NCBIncbi.nlm.nih.govVisit source
- Reference 9CANCERRESEARCHUKcancerresearchuk.orgVisit source
- Reference 10PUBMEDpubmed.ncbi.nlm.nih.govVisit source
- Reference 11MYELOMAmyeloma.org.ukVisit source
- Reference 12CANCERcancer.caVisit source
- Reference 13MAYOCLINICmayoclinic.orgVisit source
- Reference 14CANCERcancer.govVisit source
- Reference 15HEMATOLOGYhematology.orgVisit source
- Reference 16NEJMnejm.orgVisit source
- Reference 17THELANCETthelancet.comVisit source